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confirmation i a randomized trial is needed it appears that Ambi- 
some® 1 mg/kg/d is an efficacious and cost-effective approach to 
empiric antifungal therapy in patients with prolonged neutropenia 
and fever. 
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EX VIVO EXPANDED (EVE) PERIPHERAL BLOOD PROGENITOR CELLS 
(PBPC) DEMONSTRATE RESPIRATORY BURST(RB) AND PHAGOCYTIC 
CAPACITY: A FLOW CYTOMETRIC ANALYSIS 
Tombly,, dll.R.; G,o, R.; Pa,iaglm, 3/1.; Ekh,ld, E.A.; Goolsby, C.; 
Papmltsakis, E. Z; JViilleJ; ~'KM.; ~'Ki, te'r, J.N. Diw;'ioJ2 of Hematol- 
ogy/O,cology, Nortbweste,w U, iversity, C,Oicago, IL. 
One approach to the treatment of transplant-associated n u- 
tropenia is transfusion of EVE-PBPC containing functional gran 
ulocytes and their precursors. YVe developed novel multiparame- 
ter flow cytometric assays to evaluate concomitantly the 
phenotype and function of unselected PBPC cnItured in 
cytokine-enriched media containing G-CSF, GM-CSF, Flt3L, 
IL-3, Epo, and 2% autologous plasma (AP). RB activity was stim- 
ulated with either IMLP or Zymosan plus 5% AP. Phagocytosis 
was evaluated using E. coli-FITC (Orpegen Pharma) and 5% AP. 
Day 13 cultures contained cells with both mature and imraature 
phenotypes: 23.7_+3.2% CD15+/IIb+, 29.1_+2.9% CD15+/l lb- 
/dim, 8.8_+l.8% CD15dim/11b+, and 18.0_+5.0% CD15-/11b+ 
with the remainder CD15-/ l lb-.  RB data are expressed as the 
ratio of the mean fluorescence of stinmlated to unstimulated 
ceils. Gating on the subset of mature granulocytes(CD 15+/11 b+), 
EVE ceils exhibited somewhat less RB activity than normal 
peripheral blood lcukocytes (NPBL) [8.2_+2.5 vs. 15.7-+1.9 
(Zymosan, p<0.04); 1.4-+0.2 vs. 2.3_+0.2 (fMLP, p<0.01)]. Unlike 
the mature granulocytes, the CD15+/1 ib-/dim subset, showed no 
difference in its capacity for RB comparing EVE and NPBL. 
Evaluation over the 13 day culture period showed little change in 
RB activity stimulated by fMLP, whetlaer gated or ungated for 
the mature granulocyte subset. However, with Z~nosan stimula- 
tion, the RB activity of the ungated population increased two- 
fold between days 7 and 13 [1.5+_0.4 vs. 3.0+_0.5 (p = 0.08)]most 
likely reflecting the RB activity of the increasing nmnbers of 
mature monocytes which are better stimulated by Z~nosan than 
fMLP. Phagocytic activity was determined by the ratio of FITC- 
positivity of stimulated to unstimulated samples. EVE cultures 
demonstrated the capacity for phagocytosis akhough less so than 
NPBI, [5.0_+5.2 vs. 48.6_+8.3 percent-FITC-positive (p = 0.008)]. 
In these culture conditions, EVE-PBPC acquire the nentrophil 
functions of RB and phagocytosis but do not demonstrate he full 
capacity of NPBL. This may be attributable to auto-stimulation 
of ,nature granulocytes produced in culture, decreasing the 
capacity for further stimulation. Additional studies need to be 
performed to evaluate the & vivo function of the granulocytic 
progeny of EVE-PBPC. 
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USE OF AMPLICOR® CMV MONITOR(ROCHE)FOR CMV SURVEIL- 
LANCE AFTER BLOOD AND MARROW TRANSPLANTATION 
3dram, L.; Wb#e, M.J.; Pi, ei'ro, L.; Petersol~, C.ff.; Ag,ra, E.D.; Fay, 
',7. I,K; BerJy,/a,, R.B.; Meyel; R.; l/a,ce, E.A. B<~/lor-&Tmmolls CaJ> 
cev Cel~te*', Texas 01~cology, P.A., Dallas, 7X. 
The CMV Antigenemia (CMV Ag) has been a standard for 
CMV surveillance testing over the last few years but must be 
processed within a few honrs of collection due to the instability of 
the white cells. Neutropenic patients lack a sufficient number of 
white cells to even perform the CMV Ag test. The Alnplicor 
CMV naonitor (CMV PCR) is performett on plasma and samples 
can easily be collected 24 hours a day, 7 days a week, We looked at 
268 paired smweillance blood specimens using the CMV Ag and 
CMV PCR. The results of the tests are seen in the table below. If 
a true positive is defined as any patient with either assay positive, 
then the sensitivity of the CMV PCR is 72% and the sensitivity of 
the CMV Ag is 67%. Of the I3 patients who were positive by 
Amplicor CMV, but negative by CMV Ag, 5 had less than 400 
copies/ml and 4 patients had greater than 400, but less than 1000 
copies/ml. When the antigenemia slides were reviewed on CMV 
PCR positive/Ag negative samples, 1positive cell was found for 2 
samples and 1 had several distorted cells that were not initially 
reported as positive. In conclusion, of the paired tests conducted 
in our patient population, the two tests appear to provide similar 
results. The CMV PCR offers the advantages of fewer restrictions 
with sample collection to tilne of testing and can be performed in 
neutropenic patients. Tlne Amplicor CMV Monitor is an effective 
methodology for CMV surveillance in blood and marrow trans- 
plant recipients. 
~ CMV Antigenemia IPOS ~NEG 
_ _ 
[ Amplicor CMV Monitor 1~1 I 229 I 
249 
CHANGING PATTERNS OF FUNGAL INFECTIONS IN A BLOOD AND 
MARROW TRANSPLANT PROGRAM 
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Agu,:a, E.Dd, Berry,Ta1~, R.B.1; Fay, .7. ~'K1; Pi, eiro, L.1; ~Smce, E.A. 1 
1, Baylor-&mz,~o,s Omce'r CeTm, Jv Texas 011cology, P.A., Dallas, 77~. 
2, Bccvlor UTfiversity Medical Ce~teJ; Dallas, 7782 
Fungal infections are a significant cause of morbidity and mor- 
talky after blood and naarrow transplantation (BMT). The cause 
of these infections is multifactorial and includes the use of 
broad-spectrmn a tibiotics, epidemiologic exposure (nosocomial 
and conamunity) and the overall state of immunosuppression. 
The early recognition of these pathogens in patients at risk for 
these infections is warranted and essential in reducing naorbidity 
and tnortality. We analyzed our program specific epidemiologi- 
cal database (BugSlug) to see the emerging trends in fungal 
infections in our patient population. Data was collected over a 
18 month period. All fungal isolates were r ported and entered 
into the database. During this tinae period, infections caused by 
Candida species uaade up 53% of the fungal isolates seen in our 
patients. Of the Candida species isolated, I8% were Candida 
glabrata. Of 178 total, 38 blood isolates (21%) occurred in 28 
patients. Of thc 38 blood isolates, 16 (42%) were Candida 
species and 7(18%) were Aspergillus species. There were 19 
(50%) isolates that were considered to be contaminants, both 
clinically and by speciation. All 7 Aspergillus blood isolates were 
felt to be contaminants. Although there were 3 Fusarinm isolates 
in our database, none involved the blood. Although found in 
many specimens in the database, no blood isolates were attribut- 
able to C. albicans. The Candida blood isolates by species are 
summarized in the table below. There have been 17 deaths 
(45%) in the patients who developed fungal blood isolates. Cla- 
dosporium and Curvularia were single isolates in 2 patients; both 
of which were proximate to death. Of 12 patients with can- 
didemia, only 1 remains alive and well, Candida was felt to be 
causative or contributory to death in 7 patients (64%). As with 
many other centers, we are seeing a predominance of can- 
didemia caused by non-albicans species. These organisms remain 
a significant cause of morbidity and mortality in our patient 
population. 
Species I No. of isolates 
~C. glab,-aCa 1 8 
C. k,'use;- ~ 3 - -  
C. lusitaniae i 1 
C. tropicaIis ~ - -  -1 - -  
C. parapsilosis 1 
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